RxDoctor Payments Data

David Law, MD

Interventional Cardiology · Cape Girardeau, MONPI 1285670596

Payments from drug & device makers

$16,069in general payments, 2019–2025

Across 537 payments — averaging $29.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$8K
  • Biotronik Inc.$3K
  • Johnson & Johnson$592
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$545
  • Boehringer Ingelheim$540
  • Novartis$445
  • plus $3K from 35 others
$150in research payments, 2019–2025

Across 2 payments — averaging $75.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$150

What the payments were for

  • Travel & lodging$3,64129%
  • Food & beverage$8,81570%
  • Education$2152%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,069 in reported general payments places this provider in the 55th percentile of 182 interventional cardiology providers in Missouri.

See all interventional cardiology providers in Missouri

Medicare billing

Part B allowed, 2024
$553,680
Medicare patients
2,147
Services billed
20,587

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban822$643,500
XareltoRivaroxaban732$584,840
EntrestoSacubitril/Valsartan552$387,089
JardianceEmpagliflozin408$303,921
Repatha SureclickEvolocumab217$154,531
CamzyosMavacamten11$100,372
VerquvoVericiguat40$57,153
FarxigaDapagliflozin Propanediol72$48,125
MultaqDronedarone Hcl28$37,153
Praluent PenAlirocumab59$32,884
BrilintaTicagrelor41$17,998
Ezetimibe1,051$15,810
CorlanorIvabradine Hcl27$15,673
Flecainide Acetate254$11,676
Repatha SyringeEvolocumab19$11,645

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$66$643,500822 claims
Johnson & JohnsonXarelto$592$584,840732 claims
NovartisEntresto$445$387,089552 claims
Boehringer IngelheimJardiance, Pradaxa$540$305,872419 claims
E.r. Squibb & Sons, L.L.C.Camzyos$125$100,37211 claims
AstraZenecaFarxiga, Brilinta$67$66,123113 claims
MerckVerquvo$352$57,15340 claims
Sanofi-aventis U.S. LLCMultaq$34$37,15328 claims
AmgenCorlanor$117$15,67327 claims
Esperion Therapeutics, Inc.Nexletol$39$9,51224 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 182 interventional cardiology providers in Missouri.

Other interventional cardiology in Cape Girardeau

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →